AC Immune SA - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACIU Nasdaq 2836 www.acimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AC Immune SA

US Penny Stocks Spotlight: AC Immune And Two Others To Consider - Jan 3rd, 2025 12:07 am
High Growth Tech Stocks in the United States - Jan 2nd, 2025 6:07 pm
AC Immune announces interim safety, tolerability data from ABATE Phase 1b/2 - Dec 11th, 2024 12:26 pm
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome - Dec 10th, 2024 12:00 pm
AC Immune’s stock jumps after Parkinson’s therapy shows signs of benefit - Nov 15th, 2024 5:33 pm
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 - Nov 15th, 2024 12:30 pm
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - Nov 14th, 2024 12:00 pm
AC Immune to Present at the Jefferies 2024 London Healthcare Conference - Nov 13th, 2024 12:00 pm
AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates - Nov 9th, 2024 1:21 pm
AC Immune: Q3 Earnings Snapshot - Nov 5th, 2024 12:30 pm
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - Nov 5th, 2024 12:00 pm
AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29% - Oct 28th, 2024 12:41 pm
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease - Sep 17th, 2024 11:00 am
FDA grants fast track designation to Life Molecular Imaging’s tau PET diagnostic - Aug 29th, 2024 11:13 am
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions - Aug 28th, 2024 1:00 pm
The past three years for AC Immune (NASDAQ:ACIU) investors has not been profitable - Aug 22nd, 2024 11:29 am
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates - Aug 6th, 2024 1:25 pm
AC Immune: Q2 Earnings Snapshot - Aug 6th, 2024 12:23 pm
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update - Aug 6th, 2024 11:00 am
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - Jul 31st, 2024 12:30 pm